Novo Nordisk is a legal struggle against dozens of US pharmacies and companies against dozens of US, a name, a name, a name, no way: HIS and hers. The high-profile telehavish company continues to sell Wegovy’s complex version at high prices that contribute to such copies, limiting federal restrictions and contribute to Novo.
In June, Novo accused patients who violated a short arrangement that violates the short arrangement, which allows patients to break the intellectual property and risking patients directly to consumers.
Novo spokesman, Denmark Drugler, 14 small pharmacies, telehialt providers and weight loss clinics, but refused to comment on HIS. More than 130 jobs were given in the 40 USA 40.
For respect, a spokesman defended the personalization of drugs such as the future of medicine, and said that patients and providers were used to make clinical decisions on platforms.
“Investors are pleased to see that Novo, who is more aggressive in front of the court, but why they were tried or still in court,” said Barclays analyst Emily area.
Law experts say Nova can add a company to a company to help a company’s expansion against smaller telog players, a settlement negotiations or medicinal manufacturer’s strategies.
At the same time, the presence of the Novo and HIS in advance can complicate the legal action. “Business occurs in the shadow of the law,” he said, a professor in the pharmaceutical industry and the right of his intellectual property battles in San Francisco. “Sometimes companies, a way that grew older players, documents against small players like bigger players.”
US Food and Drug Administration, May 22 for pharmacies, the Wegovy has set the last date to stop the mass-producing copies of Wegovy, an application is only a drug failure.
Hims, again Wegovy’s individual versions, nono-produced doses, said that a better patient needs. Telehealth provider claims that individual dose is legally legally legally legally.
Complex laws “are insufficient for allowing different comments and the important comments – the knowledge of the courts are not given to our knowledge,” said TD Cowen Analytics Michael Nedelcovych.
Kroub, Silbisser and Kolmykov, who are affairs against small compositions, Kroub, Silbisser and Kolmykov, said Gaston Kroubb.
“It’s a set of work done,” said Kroub. “If you want to train for a heavy championship fight, start sparring with lighter opponents.”
In addition to the trading brand violation, Novo, clinicians and the clinicians and patients accused the focus of a large number of people, which complicated a large number of people.
Intellectual Property lawyer Josh Gerben, HIS and Novo have pre-work communication, said that Nova will complicate any claims that Nova could bring.
-Magie Fick and Diana Novak Jones, Reuters